Fig. 5: BMS-984923 treatment reverses FC deficits in ADtreated mice.
a Differences in FC strength between WTveh and ADveh (left, replicated from Fig. 4a) as well as WTveh and ADTx (right) at 22 M. Positive t-values (red) indicate increased FC strength in ADveh vs. WTveh mice (left) or increased FC strength in ADTx vs. WTveh mice (right). Negative t-values (blue) indicated decreased FC strength in ADveh vs. WTveh mice (left) or decreased FC strength in ADTx vs. WTveh mice (right). Treatment effects are also displayed as vertical histograms of number of positive/negative edges (right side of each matrix), node degree maps and circle plots (below each matrix). BMS-984923 treatment appears to globally reduce FC strength differences between groups at 22 M (two-sampled t-test, MATLAB, ttest2). b Treatment effects in ADTx (22 M) relative to age-matched ADveh mice (right) or ADveh mice at 20 M (left). Positive t-values (red) indicate increased FC in ADTx vs. ADveh mice. Negative t-values (blue) indicate decreased FC strength in ADTx vs. ADveh mice. c. As in Figs. 2, 4a except here, we collapse across treatment effects (as indicated in b). Histograms indicate results from the sum. Significance is displayed as * for p <0.05, ** for p <0.01 and *** for p <0.001. Tx treatment, Veh vehicle, VIS visual cortex, AUD auditory cortex, HF hippocampal formation, HY hypothalamus, AMY amygdala, CP caudoputamen, RSP retrosplenial, ORB orbital, STR striatum, MB midbrain, TT taenia tecta, OLF olfactory, ACB nucleus accumbens, ENT entorhinal, TH thalamus. Triple network color-coding: default-mode network (DMN) in green, salience network (SN) in pink, lateral-cortical network (LCN) in orange; regions in common across all three networks (light blue), regions shared by DMN and LCN (light purple) are also shown.
